Actively Recruiting
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Led by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Updated on 2026-02-18
147
Participants Needed
19
Research Sites
231 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to establish a safe and tolerable dose of arlocabtagene autoleucel (BMS-986393) in combinations with alnuctamab, mezigdomide, iberdomide, and elranatamab in participants with relapsed and/or refractory multiple myeloma (RRMM).
CONDITIONS
Official Title
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- History of relapsed and/or refractory multiple myeloma treated with at least 3 (Part 1) or at least 1 but not greater than 3 prior anti-myeloma treatment regimens (Part 2)
- Measurable multiple myeloma as per International Myeloma Working Group criteria
- Eastern Cooperative Oncology Group performance status of 0-1
You will not qualify if you...
- Prior treatment with alnuctamab (Arm A), mezigdomide (Arm B), iberdomide (Arm C), elranatamab (Arm D), or BCMA-targeting therapy (Part 2 Arms A and D)
- Prior treatment with GPRC5D-targeting therapies
- Other protocol-defined inclusion/exclusion criteria apply
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 19 locations
1
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35294-3300
Actively Recruiting
2
Mayo Clinic in Arizona - Phoenix
Phoenix, Arizona, United States, 85054
Actively Recruiting
3
City of Hope Comprehensive Cancer Center
Duarte, California, United States, 91010
Actively Recruiting
4
Mayo Clinic in Florida
Jacksonville, Florida, United States, 32224
Actively Recruiting
5
Northside Hospital
Atlanta, Georgia, United States, 30342
Actively Recruiting
6
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States, 02215
Actively Recruiting
7
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02215
Actively Recruiting
8
Mayo Clinic in Rochester, Minnesota
Rochester, Minnesota, United States, 55905
Actively Recruiting
9
University Of Nebraska Medical Center
Omaha, Nebraska, United States, 68198
Actively Recruiting
10
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey, United States, 07601
Actively Recruiting
11
Roswell Park Cancer Institute
Buffalo, New York, United States, 14263
Actively Recruiting
12
Laura and Isaac Perlmutter Cancer Center
New York, New York, United States, 10016
Actively Recruiting
13
Local Institution - 0009
New York, New York, United States, 10032
Completed
14
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
Actively Recruiting
15
Local Institution - 0023
Pittsburgh, Pennsylvania, United States, 15232
Withdrawn
16
Tennessee Oncology
Nashville, Tennessee, United States, 37203
Actively Recruiting
17
University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
18
Arthur J.E. Child Comprehensive Cancer Centre
Calgary, Alberta, Canada, T2N 5G2
Actively Recruiting
19
Princess Margaret Cancer Centre
Toronto, Ontario, Canada, M5G 2M9
Actively Recruiting
Research Team
B
BMS Study Connect Contact Center www.BMSStudyConnect.com
CONTACT
F
First line of the email MUST contain NCT # and Site #.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here